Imago BioSciences to Present First Clinical Data for IMG-7289 At 24th Congress of the European Hematology Association

SAN FRANCISCO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/EHA24?src=hash” target=”_blank”gt;#EHA24lt;/agt;–Imago BioSciences, Inc., a clinical-stage biotechnology company
developing innovative treatments for myeloid diseases, today announced
that an abstract describing clinical data regarding their
lysine-specific demethylase (LSD1) inhibitor has been selected for an
oral presentation at the 24th Congress of the European
Hematology Association (EHA) to be held in Amsterdam, The Netherlands
from June 13-16, 2019. The abstract was published on the EHA
website
.

Title: A Phase 2A Study of the LSD1 Inhibitor IMG-7289 For the
Treatment of Myelofibrosis

Abstract Number: S832
Date:
Saturday, June 15
Time: 12:30-12:45 CEST
Location: Elicium 2

The abstract represents the first report of clinical data on IMG-7289.
The protocol of IMG-7289-CTP-102 is an ongoing Phase 1/2a clinical trial
of LSD1 inhibitor IMG-7289 in patients with high or intermediate-2 risk
myelofibrosis resistant to or intolerant of approved therapy (see
clinicaltrials.gov NCT03136185).

In accordance with EHA policies, abstracts submitted to the Annual
Congress of EHA are embargoed from the time of submission. The terms and
conditions for presentation at the Annual Congress of EHA prohibit any
additional disclosure of data or information to be presented at the
Annual Congress to be made public before the presentation.

Following the Annual Congress of EHA, a summary of the presentation will
be available in the “News” section of Imago’s
website
.

About IMG-7289

IMG-7289 is a small molecule discovered by Imago BioSciences that
inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme
regulating cytokine expression and sustaining self-renewal in malignant
hematopoietic stem/progenitor cells. In non-clinical studies, IMG-7289
demonstrated robust in vivo efficacy as a single agent and in
combination with other therapeutic agents across a range of myeloid
malignancies models including the myeloproliferative neoplasms which
encompass myelofibrosis, essential thrombocythemia and polycythemia
vera. IMG-7289 also shows activity against solid tumors in combination
with other checkpoint agents in non-clinical models. IMG-7289 is under
evaluation for the treatment of acute myeloid leukemia (see
clinicaltrials.gov NCT02842827).

About Imago BioSciences

Imago BioSciences is a clinical-stage, venture-backed pharmaceutical
company whose investors include Frazier Healthcare Partners, Omega
Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron,
Greenspring Associates and Xeraya Capital as well as other corporate and
venture investors. Imago is focused on improving the management of
malignant and life-threatening diseases of the bone marrow and
modulation of the immune system. The Company is currently focused on
neoplastic diseases of the bone marrow including acute myeloid leukemia,
myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential
thrombocythemia. The Company is based in California.

Please see the website at www.imagobio.com
for additional information.

Contacts

Investor and Media Contact:
Laura Eichorn
laura@imagobio.com
415-529-5055


DutchNews.nl has been free for 12 years, but now we are asking our readers to help. Your donation will enable us to keep providing you with fair and accurate news and features about all things Dutch.
Donate via Ideal, credit card or Paypal.